Latest Healthcare Diagnostics News

Optiscan Imaging has entered a three-year strategic collaboration with Australian Clinical Labs to validate and deploy its InForm™ digital pathology platform, aiming to transform diagnostic workflows with real-time tissue analysis.

Archer Materials has partnered with CSIRO to develop cutting-edge quantum machine learning models aimed at revolutionizing fraud detection in financial transactions.

Artrya Limited has successfully navigated a key FDA Q-Submission meeting, receiving clear guidance on the regulatory pathway for its Salix Coronary Flow module, with a 510(k) submission planned by year-end.

Micro-X reported FY25 revenue of $13.1 million, underpinned by significant US government contracts and pioneering 3D head CT imaging technology, setting the stage for clinical trials and commercial expansion.

Lumos Diagnostics reported an 11.4% revenue increase to US$12.4 million for FY2025, yet still posted a significant net loss amid auditor concerns over its future viability.

Advanced Health Intelligence Ltd (AHI) reports robust commercial progress and strategic funding moves in Q1 2025 despite ongoing ASX trading suspension and recent NASDAQ delisting. Key partnerships and technology validations position the company for a strong global scale-up.

Lumos Diagnostics Holdings Limited has had its ASX trading suspension lifted following news of a strategic material agreement, signaling potential growth ahead.

Lumos Diagnostics has voluntarily suspended its ASX trading pending a market announcement about strategic agreements, signaling potential shifts in its business trajectory.

Micro-X has successfully met key development milestones worth $2.3 million across contracts with ARPA-H, Billion Prima, and the US Department of Homeland Security, marking steady progress in its innovative medical and security imaging technologies.

Atomo Diagnostics Limited has announced a capital raising initiative comprising a Share Purchase Plan (SPP) and a Placement, aiming to raise up to $1 million through the SPP and additional funds via a Placement, subject to shareholder approval at a June 23 meeting.